National Capital Consortium for Pediatric Device Innovation 2.0

国家儿科器械创新2.0资本联盟

• 批准号: 9768954
• 负责人: WILLIAM E. BENTLEY
• 金额: $ 100万
• 依托单位: CHILDREN'S RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-01 至 2023-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9768954
• 关键词: National; Capital; Consortium; Pediatric; Device

ABSTRACT NCC-PDI’s mission is to facilitate the development and commercialization of devices that are indicated for use in pediatric patients or that are intended to treat, diagnose, or cure diseases from which pediatric patients suffer. The Consortium has served as an accelerator to medical device innovators that intend to label their device for use, in the United States, in the general pediatric population or a subpopulation. The Food and Drug Administration’s report to Congress on “FY 2016 Premarket Approval of Pediatric Uses of Devices” indicates that over a 9-year period (2008-2016), an average of almost nine devices were approved per year that were indicated for pediatric patients; this equated to an average of 20.5 percent Pre-market Approvals (PMAs) and Humanitarian Device Exemptions (HDEs) over this time. This represents a formidable progress that was achieved thanks in large to the Pediatric Medical Device Safety and Improvement Act (PMDSIA) of 2007. A closer look at the data, however, suggests that the majority of these approved devices are labeled for the adolescent subpopulation (12 years through 21 years of age) in addition to older adults. There still remains a significant unmet need for devices labeled for subpopulations of neonates (birth until 1 month of age), infants (1 month until 2 years of age), and children (2 years until 12 years of age). NCC-PDI’s long-term goal under this RFA is to contribute to the national effort to address this gap and help bring more devices to market. Our short-term and operational goals are to continuously enhance our capabilities in providing expert advising and support services to innovators of pediatric medical devices, focusing on the total product life cycle for medical devices from concept, through pre-market development, to commercialization. We will reach our long-term and short-term goals by achieving the following specific aims. Specific Aim 1. Enhance the pipeline of high-growth pediatric device entrepreneurs with special considerations given to those who focus on the unmet needs of subpopulations of neonates, infants, and children. Specific Aim 2. Foster the advance of pediatric medical devices through access to a platform of experienced business, regulatory, reimbursement, medicine & science, engineering & prototyping, and trials design. Specific Aim 3. Through implementation of demonstration projects, develop, verify and operationalize methods of evidence generation and data usage, and demonstrate scalability across diverse devices and diseases. Our Consortium consists of lead members (Children’s National Health System and University of Maryland), members (BioHealth Innovation, MedTech Innovator, HealthCore/NERI, and Resnick, Chodorow, & Associates), and extended members (Smithwise, Cadence, I-ACT, PEDSnet, Bear Institute/Cerner, Digital Infuzion, Epidarex, Medical Murray, SFA Regulatory, CTSI-CN, CALCE, M-CERSI).

摘要 NCC-PDI的使命是促进适用器械的开发和商业化 用于儿科患者或用于治疗、诊断或治愈儿科患者 受苦该联盟已成为医疗器械创新者的加速器，这些创新者打算将其 在美国用于一般儿科人群或亚群的器械。食品药品 政府向国会提交的关于“2016财年儿科使用器械的上市前批准”的报告表明， 在9年期间（2008-2016），平均每年批准近9种器械， 适用于儿科患者;这相当于平均20.5%的上市前批准（PMA）， 人道主义器械豁免（HDE）。这是一个巨大的进步， 这主要归功于2007年《儿科医疗器械安全和改进法案》（PMDSIA）。一 然而，仔细研究数据表明，大多数这些批准的设备都标有 青少年亚群（12岁至21岁）以及老年人。仍然存在 对标记用于新生儿亚群（出生至1个月）的器械的显著未满足需求， 婴儿（1个月至2岁）和儿童（2岁至12岁）。NCC-PDI长期 该RFA的目标是为解决这一差距的国家努力做出贡献，并帮助将更多的设备带到 市场我们的短期和业务目标是不断提高我们在提供专家服务方面的能力， 为儿科医疗器械创新者提供咨询和支持服务，重点关注整个产品生命周期 医疗器械从概念、上市前开发到商业化。我们将到达我们的 通过实现以下具体目标，实现长期和短期目标。具体目标1.加强管道 高增长的儿科器械企业家，特别考虑那些专注于 新生儿、婴儿和儿童亚群的未满足需求。具体目标2。促进...的发展 儿科医疗器械通过进入一个平台，经验丰富的业务，监管，报销， 医学与科学、工程与原型设计以及试验设计。具体目标3。通过实施 示范项目，制定、核实和实施证据生成和数据使用方法， 并展示了在不同设备和疾病之间的可扩展性。我们的联盟由主要成员组成 （儿童国家卫生系统和马里兰州大学），成员（生物健康创新，医疗技术 Innovator，HealthCore/NERI和Resnick，Chodorow，& Associates）和扩展成员（Smiths， Cadence、I-ACT、PEDSnet、Bear Institute/Cerner、Digital Infuzion、Epidarex、Medical Murray、SFA Regulatory、 CTSI-CN、CALCE、M-CERSI）。